Neurocrine Biosciences Inc.’s tardive dyskinesia candidate, NBI-98854, nailed its endpoints in a Phase IIb (Kinect 2) study by causing a significant change from baseline in the abnormal involuntary movement scale (AIMS) after six weeks of treatment. Tardive dyskinesia is a syndrome characterized by involuntary, repetitive movements of the extremities. It has no approved treatment and is rarely reversible.